Beta Bionics, Inc. (BBNX) Form 424B5 — Sep 15, 2026
Beta Bionics (Nasdaq: BBNX) filed a preliminary prospectus supplement for a $125,000,000 offering of common stock, with J.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners as joint book-running managers and a 30-day option for up to $18,750,000 of additional shares. The final offering price has not yet been set; the stock last traded at $16.73 on September 14, 2026 versus a net tangible book value of $5.70 per share, and new investors face what the company itself calls immediate and substantial dilution. Proceeds are earmarked for general corporate purposes, led by costs to commercialize Mint, including manufacturing expansion.
Key figures
- Gross Proceeds
- 125000000
- Shares Outstanding
- 44981606
- Greenshoe usd
- 18750000
- Greenshoe period
- 30 days
- Rsus outstanding
- 2424161
- Lockup period days
- 60
- Annual revenue note
- annual revenue exceeded $100.0 million in most recent fiscal year (no longer a smaller reporting company)
- Options outstanding
- 6913527
- Mint pharmacy coverage
- ~40% of insured U.S. lives at launch, targeted to at least 50% within first year
- Net tangible book value total
- $256.0 million as of June 30, 2026
- Mint 2027 manufacturing capacity
- at least 1.5 million disposable units
- Net tangible book value per share
- 5.7
- Last reported sale price 2026 09 14
- 16.73
- Options weighted avg exercise price
- 10.23
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.